ADIL - MCAP CO - Adial Pharmaceuticals

Due to the absence of external economic risks and operations within the US legal framework, the business functions in a stable environment. This historical price chart for Adial Pharmaceuticals (ADIL) demonstrates the dynamics of an asset with a market capitalization of 0.01. Adial Pharmaceuticals (ADIL) generates revenue from alcoholism treatments, targeting patients with a hereditary predisposition. The project faces pressure from government programs and the risk of expansion by pharmaceutical behemoths into this niche segment.

For Adial Pharmaceuticals (ADIL), the current market capitalization reflects the market value of all outstanding shares. This figure is calculated as the product of the price of a single instrument and the total number of securities. The metric measures the aggregate capital that investors are willing to allocate toward the development of AD04 personalized therapy. The price action reflects market confidence in the genetic approach to addictology. Trend analysis helps determine the asset's accumulation phase prior to potential growth.